Quest Diagnostics vs Guardant Health
DGX and GH side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DGX and GH compare
Quest Diagnostics is the larger company, worth 1.2 times as much as Guardant Health ($27.8B against $24.0B).
Guardant Health grew revenue faster over the last twelve months (42.7% versus 9.9% for Quest Diagnostics).
Quest Diagnostics keeps more of each dollar of sales as profit, with a net margin of 9.2% compared with −38.3% at Guardant Health.
Quest Diagnostics pays a dividend yielding 1.3%; Guardant Health does not pay one.
Quest Diagnostics scores higher on the StockData Score (12 against 9 for Guardant Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DGX | GH |
|---|---|---|
| Size and price | ||
| Market cap | $27.8B | $24.0B |
| Share price | $251.82 | $178.80 |
| Change, 1 year | 44.1% | 147% |
| Change, 5 years | 79.2% | 62.3% |
| Beta (5Y) | 0.33 | 1.61 |
| Employees | 57K | 2,506 |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 0 | 0 |
| Growth score | 3 | 3 |
| Performance score | 3 (better) | 1 |
| Health score | 3 | 5 (better) |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 26.8× | – |
| P/S | 2.4× (better) | 20.3× |
| P/B | 3.7× | – |
| EV/EBITDA | 15.0× | – |
| P/FCF | 20.6× | – |
| PEG | 8.47 | – |
| FCF yield | 4.9% (better) | −1.0% |
| Fair value | $251.80 | – |
| Margin of safety | −0.01% | – |
| Growth | ||
| Revenue growth (TTM) | 9.9% | 42.7% (better) |
| Revenue growth, 5Y average | 3.2% | 27.9% (better) |
| Net income growth (TTM) | 11.8% | – |
| EPS growth (TTM) | 13.2% | – |
| EPS growth, 5Y average | −3.5% | – |
| Profitability | ||
| Gross margin | 33.1% | 65.0% (better) |
| Operating margin | 14.1% (better) | −39.7% |
| Net margin | 9.2% (better) | −38.3% |
| FCF margin | 11.7% (better) | −20.3% |
| Return on equity | 14.4% | – |
| Return on invested capital | 10.0% | – |
| Financial health | ||
| Debt / equity | 0.75 | – |
| Net debt / EBITDA | 2.27 | – |
| Interest coverage | – | −97.6× |
| Current ratio | 1.59 | 4.03 (better) |
| Altman Z-score | 3.76 | 4.83 (better) |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 1.3% | – |
| Payout ratio | 34.2% | – |
| Buyback yield | – | 0.00% |
| Shareholder yield | 1.3% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 95.1% | 99.8% |
| Held by insiders | 0.47% | 1.9% |
| Insider net buying, 12 months | −$37.0M (better) | −$174M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 3.1% | 9.1% |
Go deeper
- DGX stock overview
- DGX income statement
- DGX valuation and score
- GH stock overview
- GH income statement
- GH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.